BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Benzoxaborole-based CPSF3 inhibitor to treat infections

DISEASE CATEGORY: Infectious disease INDICATION: Cryptosporidium Inhibiting the Cryptosporidium CPSF3 homolog with AN3661 could treat infections by the parasite, which can be lethal in young children and immunocompromised individuals. Anacor Pharmaceuticals Inc., which Pfizer Inc....
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BC Innovations | Dec 5, 2017
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination...
BC Week In Review | Apr 29, 2013
Clinical News

NT-300: Phase III started

Romark began a double-blind, placebo-controlled, international Phase III trial to compare twice-daily 600 mg NT-300 alone or in combination with twice-daily 75 mg oral Tamiflu oseltamivir for 5 days vs. Tamiflu alone or placebo in...
BC Innovations | Nov 8, 2012
Tools & Techniques

MuSIC by design

A Harvard Medical School and Tsinghua University team has developed a technology, dubbed MuSIC, that identifies synergistic drug pairs. 1 The group showed proof of concept by finding new combinations of therapeutics for HIV, but...
BC Innovations | Oct 25, 2012
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Multiplex screening for interacting compounds (MuSIC) to help identify drug combinations to treat HIV/AIDS MuSIC could be used to help identify drug combinations to...
BC Innovations | Aug 25, 2011
Targets & Mechanisms

More than one way to stop HCV

A French team led by Epixis S.A. has developed an HCV vaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques. 1 Because of the ability to elicit both types of...
BC Week In Review | Nov 15, 2010
Clinical News

Alinia nitazoxanide: Pilot trial data

An open-label pilot trial in 5 liver transplant patients showed that oral Alinia reduced HCV viral load in all patients during the first 72 hours post-transplant. However, HCV RNA levels were similar to pre-transplant levels...
BC Week In Review | Nov 1, 2010
Clinical News

Hepatitis C vaccine: Phase II start

Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without Pegasys peginterferon...
Items per page:
1 - 10 of 58